 Marc Mathias
Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 12 | 2023 | 164 | 1.940 |
Why?
| | Geographic Atrophy | 7 | 2025 | 79 | 1.220 |
Why?
| | Visual Acuity | 9 | 2025 | 356 | 0.740 |
Why?
| | Wet Macular Degeneration | 4 | 2025 | 56 | 0.680 |
Why?
| | Retinal Drusen | 3 | 2021 | 31 | 0.520 |
Why?
| | Eye Infections, Bacterial | 2 | 2015 | 28 | 0.490 |
Why?
| | Orbital Cellulitis | 1 | 2012 | 17 | 0.370 |
Why?
| | Endophthalmitis | 3 | 2017 | 29 | 0.360 |
Why?
| | Complement Factor B | 2 | 2022 | 109 | 0.330 |
Why?
| | Registries | 5 | 2024 | 2035 | 0.320 |
Why?
| | Complement Activation | 2 | 2025 | 415 | 0.310 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 234 | 0.300 |
Why?
| | Tomography, Optical Coherence | 5 | 2025 | 213 | 0.280 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 400 | 0.270 |
Why?
| | Choroid Diseases | 2 | 2023 | 10 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 43 | 0.240 |
Why?
| | Vitreous Body | 2 | 2015 | 110 | 0.220 |
Why?
| | Diseases in Twins | 1 | 2024 | 169 | 0.210 |
Why?
| | Retinal Degeneration | 1 | 2023 | 38 | 0.200 |
Why?
| | Twins | 1 | 2024 | 243 | 0.200 |
Why?
| | Retinopathy of Prematurity | 1 | 2024 | 142 | 0.200 |
Why?
| | Vitrectomy | 3 | 2025 | 70 | 0.190 |
Why?
| | Birth Weight | 1 | 2024 | 516 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | Fluorescein Angiography | 4 | 2023 | 151 | 0.180 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 135 | 0.160 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 25 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 39 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 42 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 146 | 0.150 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.150 |
Why?
| | Internet | 1 | 2023 | 655 | 0.150 |
Why?
| | Anterior Eye Segment | 1 | 2017 | 9 | 0.140 |
Why?
| | Strabismus | 1 | 2017 | 29 | 0.130 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2017 | 58 | 0.130 |
Why?
| | Automobile Driving | 1 | 2018 | 148 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2025 | 15657 | 0.120 |
Why?
| | Retinal Vein Occlusion | 1 | 2015 | 13 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5131 | 0.120 |
Why?
| | Needles | 1 | 2015 | 59 | 0.120 |
Why?
| | Female | 17 | 2025 | 73304 | 0.120 |
Why?
| | Biopsy, Needle | 1 | 2015 | 189 | 0.110 |
Why?
| | Aged | 11 | 2025 | 23961 | 0.110 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7635 | 0.110 |
Why?
| | Humans | 24 | 2025 | 137585 | 0.110 |
Why?
| | Self Report | 1 | 2018 | 827 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 5778 | 0.110 |
Why?
| | Ischemia | 1 | 2017 | 409 | 0.110 |
Why?
| | Fibrin | 1 | 2014 | 81 | 0.110 |
Why?
| | Male | 14 | 2025 | 67762 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2015 | 229 | 0.100 |
Why?
| | Retina | 1 | 2015 | 298 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.100 |
Why?
| | Diabetic Retinopathy | 1 | 2014 | 189 | 0.090 |
Why?
| | Eyelid Diseases | 1 | 2012 | 19 | 0.090 |
Why?
| | Ocular Motility Disorders | 1 | 2012 | 27 | 0.090 |
Why?
| | Edema | 1 | 2012 | 130 | 0.090 |
Why?
| | Biomarkers | 4 | 2023 | 4149 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 804 | 0.080 |
Why?
| | Atrophy | 2 | 2023 | 184 | 0.080 |
Why?
| | Time Factors | 3 | 2025 | 6828 | 0.080 |
Why?
| | Bacteria | 1 | 2015 | 858 | 0.070 |
Why?
| | Choroid | 2 | 2021 | 62 | 0.070 |
Why?
| | Odds Ratio | 2 | 2019 | 1070 | 0.060 |
Why?
| | Colorado | 3 | 2022 | 4565 | 0.060 |
Why?
| | Quality of Life | 3 | 2022 | 2892 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2015 | 1809 | 0.060 |
Why?
| | Middle Aged | 6 | 2019 | 33479 | 0.060 |
Why?
| | Infant | 2 | 2025 | 9465 | 0.060 |
Why?
| | Risk Factors | 3 | 2025 | 10388 | 0.060 |
Why?
| | Child, Preschool | 2 | 2025 | 11074 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 216 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2014 | 2654 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3196 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2691 | 0.050 |
Why?
| | Gestational Age | 1 | 2024 | 910 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 168 | 0.040 |
Why?
| | Vision Disorders | 1 | 2022 | 142 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 110 | 0.040 |
Why?
| | Inflammation | 2 | 2023 | 2837 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 56 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 236 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2012 | 3566 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 93 | 0.040 |
Why?
| | Adolescent | 2 | 2025 | 21513 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 410 | 0.040 |
Why?
| | Child | 2 | 2025 | 21935 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2020 | 5472 | 0.040 |
Why?
| | Prospective Studies | 2 | 2020 | 7604 | 0.040 |
Why?
| | Disease Progression | 1 | 2025 | 2757 | 0.030 |
Why?
| | Iris Diseases | 1 | 2017 | 6 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 496 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 852 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 762 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 726 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 120 | 0.030 |
Why?
| | Young Adult | 1 | 2012 | 13209 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1509 | 0.030 |
Why?
| | Intravitreal Injections | 1 | 2015 | 56 | 0.030 |
Why?
| | Macular Edema | 1 | 2015 | 43 | 0.030 |
Why?
| | Bevacizumab | 1 | 2015 | 138 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 2074 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1009 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1111 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 6079 | 0.030 |
Why?
| | Adult | 2 | 2015 | 37929 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 545 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3556 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5742 | 0.020 |
Why?
| | Models, Biological | 1 | 2015 | 1783 | 0.020 |
Why?
| | United States | 1 | 2020 | 14841 | 0.010 |
Why?
|
|
Mathias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|